Robert Conry, MD
Hematology & Oncology · Birmingham, ALNPI 1548203235
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $124,432 of the $142,533 with a category attached, or 87.3%. 33 manufacturers reported payments, led by Novartis at 27.6% of the total. Reporting peaked in 2019 at $130,575 and has fallen 98.7% since, to $1,693 in 2025. Among hematology & oncology clinicians in AL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 301 payments — averaging $473.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$39K
- Array Biopharma Inc$37K
- Merck$26K
- E.r. Squibb & Sons, L.L.C.$17K
- Sanofi$12K
- Regeneron Healthcare Solutions, Inc.$5K
- plus $6K from 27 others
Across 89 payments — averaging $8393.29 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$384K
- Genentech, Inc.$168K
- Dynavax Technologies Corporation$122K
- Novartis$62K
- Array Biopharma Inc$9K
- E.r. Squibb & Sons, L.L.C.$2K
What the payments were for
- Consulting fees$4,1203%
- Speaking & faculty fees$124,43287%
- Travel & lodging$7,0345%
- Food & beverage$4,7663%
- Education$160%
- Other$2,1652%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 87 | $39,278 |
| Array Biopharma Inc | 34 | $37,316 |
| Merck | 49 | $25,726 |
| E.r. Squibb & Sons, L.L.C. | 21 | $17,145 |
| Sanofi | 9 | $11,813 |
| Regeneron Healthcare Solutions, Inc. | 5 | $4,943 |
| Pfizer | 13 | $3,690 |
| Bristol Myers Squibb | 13 | $1,091 |
| Gilead(2 entities) | 9 | $181 |
| Daiichi Sankyo Inc. | 7 | $167 |
| Johnson & Johnson | 6 | $131 |
| Galt Pharmaceuticals, LLC | 1 | $128 |
| AbbVie | 6 | $118 |
| Pharmacyclics LLC, An Abbvie Company | 6 | $107 |
| Deciphera Pharmaceuticals Inc. | 4 | $101 |
| GSK | 4 | $76 |
| AstraZeneca | 4 | $70 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $63 |
| Eisai Inc. | 3 | $55 |
| Seagen Inc. | 3 | $52 |
| Stemline Therapeutics Inc. | 2 | $52 |
| Exelixis Inc. | 1 | $27 |
| AVEO Pharmaceuticals, Inc. | 1 | $22 |
| Taiho Oncology, Inc. | 1 | $22 |
| Karyopharm Therapeutics Inc. | 1 | $22 |
| Blueprint Medicines Corporation | 1 | $21 |
| Genentech USA, Inc. | 1 | $21 |
| ADC Therapeutics America, Inc. | 1 | $17 |
| Global Blood Therapeutics, Inc. | 1 | $17 |
| Rigel Pharmaceuticals, Inc. | 1 | $16 |
| Beone Medicines USA, Inc. | 1 | $16 |
| Agios Pharmaceuticals, Inc. | 1 | $14 |
| EMD Serono, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$142,533 in reported general payments places this provider in the 95th percentile of 177 hematology & oncology providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RevlimidLenalidomide | 62 | $1,066,138 |
| ImbruvicaIbrutinib | 47 | $1,018,837 |
| PomalystPomalidomide | 43 | $931,511 |
| XtandiEnzalutamide | 55 | $792,792 |
| JakafiRuxolitinib Phosphate | 37 | $647,940 |
| Lenalidomide | 43 | $542,118 |
| BrukinsaZanubrutinib | 49 | $522,225 |
| FruzaqlaFruquintinib | 16 | $396,461 |
| BraftoviEncorafenib | 16 | $318,696 |
| PromactaEltrombopag Olamine | 22 | $304,879 |
| MektoviBinimetinib | 16 | $249,686 |
| MekinistTrametinib Dimethyl Sulfoxide | 21 | $249,612 |
| TafinlarDabrafenib Mesylate | 20 | $238,891 |
| IbrancePalbociclib | 13 | $208,550 |
| Pazopanib Hcl | 35 | $172,401 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bristol Myers SquibbRevlimid | $1,091 | $1,066,13862 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $107 | $1,018,83747 claims |
| NovartisPromacta, Mekinist, Tafinlar, Kisqali | $39,278 | $952,40775 claims |
| E.r. Squibb & Sons, L.L.C.Pomalyst | $17,145 | $931,51143 claims |
| Array Biopharma IncBraftovi, Mektovi | $37,316 | $568,38232 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Fruzaqla | $63 | $396,46116 claims |
| PfizerIbrance, Trazimera, Eliquis | $3,690 | $279,90652 claims |
| Genentech USA, Inc.Erivedge | $21 | $150,31011 claims |
| AstraZenecaCalquence | $70 | $128,51013 claims |
| AbbVieVenclexta | $118 | $102,52817 claims |
| Johnson & JohnsonXarelto | $131 | $21,36029 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 177 hematology & oncology providers in Alabama.
Other hematology & oncology in Birmingham
- Amitkumar MehtaBirmingham$683K
- Pankit VachhaniBirmingham$545K
- Luciano CostaBirmingham$409K
- Khaleel AshrafBirmingham$379K
- Michael BirrerBirmingham$302K
- Rudolph NavariBirmingham$254K
- Mayur NarkhedeBirmingham$193K
- Midhun MallaBirmingham$144K
- David MooneyBirmingham$120K
- Christos VaklavasBirmingham$97K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.